Protocol Ledger

NCT07390123 · Phase III · RECRUITING

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Interventional Phase III clinical trial protocol NCT07390123 sponsored by Haisco Pharmaceutical Group Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-07 Enrollment: 370 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07390123
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)370 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07390123
Protocol FieldVerified Registry Value
NCT IdentifierNCT07390123
Consolidated Lead SponsorHaisco Pharmaceutical Group Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment370 participants (ESTIMATED)
Registered Start Date2026-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07390123
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
The Second Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI